CH Biotech R&D Co Ltd

CH Biotech R&D Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.25, indicating limited leverage. The company's liquidity position is moderate, with a current ratio of 1.21 and cash and equivalents of TWD 248.3 million. However, net cash is negative after subtracting total debt, signaling potential short-term liquidity constraints. Profitability metrics show strong performance, with a return on equity (ROE) of 17.27% and return on assets (ROA) of 12.98%. These figures exceed the industry median for Agricultural Chemicals, where ROE typically ranges between 10% and 15%. Gross margin of 83.9% and operating margin of 34.2% also reflect efficient cost management and pricing power. Geographically, the company distributes its products across North America, South America, Australia, and Asia, with no disclosed revenue concentration in any single region. This diversification reduces exposure to regional economic downturns. The company operates in a single business segment, with all revenue derived from agricultural biotechnology products. The company's growth trajectory is positive, with a current fiscal year (FY) revenue outlook of 8.2% year-over-year growth and a next FY outlook of 10.5% growth. This aligns with the industry's moderate expansion in demand for sustainable agricultural inputs. Historical revenue growth has averaged 6.5% annually over the past three years. Risk factors include moderate liquidity risk due to negative net cash and a low dilution potential, as shares outstanding remain unchanged between basic and diluted measures. No recent equity issuance or ATM/shelf registration has been disclosed, and the company has not flagged dilution in 10-K Risk Factors. Recent events include the launch of MegaGro 2.0 (Radiate NEXT) and NutriSync 3D, which are expected to drive incremental revenue in the next fiscal year. No material regulatory or litigation events have been disclosed in the latest filings.